Pharma Mar, S.A. (0RC6.L)
| Previous close | 73.87 |
| Open | 74.18 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 97.50 - 107.10 |
| 52-week range | 29.46 - 107.10 |
| Volume | |
| Avg. volume | 6,874 |
| Market cap | 16.387B |
| Beta (5Y monthly) | 0.09 |
| PE ratio (TTM) | 0.15 |
| EPS (TTM) | 5.03 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.3 Growth Companies With High Insider Ownership And Up To 23% Revenue Growth
As global markets exhibit mixed signals with the S&P 500 reaching new highs and sectors like technology leading the charge, investors are navigating through a landscape shaped by fluctuating interest rates and economic indicators. In such a market, growth companies with high insider ownership can be particularly compelling, as this combination often signals strong confidence in the company’s future from those who know it best.
Simply Wall St.Exploring Three Growth Companies Where Insiders Hold The Reins
As global markets navigate through a landscape marked by fluctuating inflation rates and shifting monetary policies, investors are keenly observing the impact on various stock sectors. In this environment, growth companies with high insider ownership can offer unique advantages, as insiders' substantial equity stakes often align their interests closely with those of shareholders, potentially fostering robust governance and strategic consistency amidst market volatility.
PR NewswirePharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer
PharmaMar (MSE: PHM), world leader in the discovery, development and commercialization of marine-derived cancer treatments, presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States.
